Toward a Biologic Therapy to Improve Stroke Outcomes After Thrombolytic Therapy
Stroke is a devastating event especially in the lives of the elderly and remains a worldwide public health problem. In the United States alone, the prevalence of stroke is 8.8 million people and stroke is responsible for 200,000 deaths annually, almost 1 out of every 16 deaths.1 Every 40 seconds, someone in the United States has a new stroke that results in 800,000 new strokes annually. Of those who do survive, many are disabled: stroke is the most common cause of disability worldwide, and costs associated with its effects are estimated to be over $60 billion per year in the United States alone. 2
- Received October 21, 2015.
- Accepted October 22, 2015.